2. Academic Validation
  3. A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)

A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)

  • J Med Chem. 2009 Apr 9;52(7):1799-802. doi: 10.1021/jm900093d.
Wei Li 1,  Jianchang Li,  Yuchuan Wu,  Junjun Wu,  Rajeev Hotchandani,  Kristina Cunningham,  Iain McFadyen,  Joel Bard,  Paul Morgan,  Franklin Schlerman,  Xin Xu,  Steve Tam,  Samuel J Goldman,  Cara Williams,  Joseph Sypek,  Tarek S Mansour
Affiliations

Affiliation

  • 1 Chemical Sciences, Inflammation, and Drug Safety and Metabolism, Wyeth Research, Cambridge, Massachusetts 02140, USA.
PMID: 19278250 DOI: 10.1021/jm900093d
Abstract

Matrix metalloprotease 12 plays a significant role in airway inflammation and remodeling. Increased expression and production of MMP-12 have been found in the lung of human COPD patients. MMP408 (14), a potent and selective MMP-12 Inhibitor, was derived from a potent matrix metalloprotease 2 and 13 inhibitor via lead optimization and has good physical properties and bioavailability. The compound blocks rhMMP-12-induced lung inflammation in a mouse model and was advanced for further development for the treatment of COPD.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z